ClinicalTrials.gov
public full text
Public Domain
A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China
breast-cancercolorectal-canceresophageal-squamous-cell-carcinomahead-and-neck-squamous-cell-carcinomanon-small-cell-lung-cancer
This is a Phase 1, open-label dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) and assess the DLT of JAB-3312. It is anticipated that approximately 24 subjects will be enrolled in the dose-escalation phase of the study. JAB-3312 will be administered orally once daily (QD) in 21-day treatment cycles.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors#1058296
- A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors#1161441
- Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors#896777
- Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors#906675
- Study of BM230 in Patients With Advanced Solid Tumors#855698
Record · ID 906979
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive